Decentralized Clinical Trials (DCTs) are transforming the landscape of clinical research by leveraging digital technologies to facilitate remote patient participation. This patient-centric approach not only benefits participants but also ensures more inclusive and robust study results while reducing the workload for investigators. In the aftermath of the pandemic, a hybrid model is emerging that seamlessly integrates technology with traditional site workflows, ushering in a new era of clinical trials that harnesses the strengths of both approaches. In a financially constrained environment, DCT platform providers are looking to strike a balance between client satisfaction and cost reduction. They prioritize delivering comprehensive solutions that include real-world evidence, integration with sensors and wearables, and tools dedicated to enhancing patient engagement and retention throughout the trial process. This compendium provides detailed and fact-based snapshots of 22 DCT providers. Each profile offers a comprehensive picture of the provider’s offerings, technology solutions, key clients, recent developments, and investments. Scope Industry: Life sciences Geography: global Contents This report features 22 DCT platform provider profiles and includes: Company overview: the company’s mission, client base, and revenue split across buyer segment and geographies Case studies demonstrating DCT capabilities Solutions/Products enabling DCT capabilities Recent product developments, partnerships, and investment areas Membership(s) Clinical Development Technology Outsourcing Excellence

Decentralized Clinical Trials (DCTs) are transforming the landscape of clinical research by harnessing digital technologies to facilitate remote patient participation. This patient-centric approach not only benefits participants but also ensures more inclusive and robust study results while reducing the workload for investigators. In the post-pandemic climate, a hybrid model is emerging that seamlessly integrates technology advances with traditional site workflows, creating a new era of clinical trials that harnesses the strengths of both. In a funding-constrained environment, DCT platform providers are looking to strike a balance between client satisfaction and cost reduction. They are focusing on delivering comprehensive solutions that include real-world evidence, integration with sensors and wearables, and tools dedicated to enhancing patient engagement and retention throughout the trial process. In this report, we assess the capabilities of 22 platform providers specific to the decentralized clinical trial landscape. These platform providers are mapped on the Everest Group PEAK Matrix® , a composite index of a range of distinct metrics related to a provider’s capability and market impact. Scope Industry: Life sciences clinical development technology Geography: global Contents In this report, we: Examine the provider landscape for DCTs Assess DCT platform providers on several capabilities and market success-related dimensions Membership(s) Clinical Development Technology Sourcing and Vendor Management

The concept of impact sourcing has experienced remarkable growth and acceptance across geographies. Service providers have recognized the potential of leveraging impact sourcing to simultaneously achieve business objectives and create positive social change. Through targeted hiring practices, these organizations have tapped into a talent pool that was previously underserved, providing opportunities for personal growth, skill development, and economic empowerment. Despite the evident benefits of impact sourcing, the lack of a comprehensive and guided approach has hindered its widespread adoption. Service providers have encountered challenges in formulating a clear strategy and framework to integrate impact sourcing into their operations. The absence of a structured playbook has made it difficult for organizations to navigate the complexities and nuances associated with implementing impact sourcing initiatives. In this report, we provide a detailed understanding of impact sourcing, its nuances, stakeholders involved, and the benefits and challenges. Along with this, we share a stepwise approach to help service providers develop a robust strategy for successful implementation. We have also shared case studies from successful implementations to inspire and inform service providers. Scope All industries and geographies Contents This report looks at: An overview of the talent market and the ecosystem of impact sourcing Developing a sustainable impact sourcing strategy for service providers Sharing a perspective on the future of impact sourcing Impact sourcing case studies compendium Membership(s) Sustainability Technology and Services Sourcing and Vendor Management

The pandemic accelerated the need to extract value from data due to the substantial increase in data generation from various clinical sources, characterized by high veracity, variety, and volume. As a result, the adoption of clinical Data and Analytics (D&A) platforms in clinical development has notably surged. This prompted a considerable interest in assessing their impact on clinical trials, patient care, treatment outcomes, and health system efficiency. The integration of complex clinical data sources including Electronic Health Records (EHR), Electronic Medical Records (EMR), laboratory data, Clinical Trial Management Systems (CTMS), connected devices, and Real-world Data (RWD), presents a significant challenge that the industry currently faces. Clinical D&A platforms provide significant benefits in the realm of clinical development. These platforms enhance data management by facilitating centralized and standardized data collection from various sources, resulting in improved data quality and integrity. Real-time monitoring capabilities enable stakeholders to track trial progress, identify potential issues, and make informed decisions. Advanced analytics tools help uncover patterns, trends, and correlations within the data, providing valuable insights for optimizing trial protocols and treatment strategies. In this compendium, we provide comprehensive and fact-based snapshots of 14 platform providers specific to clinical D&A. In addition, each provider is positioned on Everest Group’s PEAK Matrix® for comparison. The compendium will enable providers to benchmark their capabilities against their competitors, while buyers of clinical D&A platforms will be able to assess the providers based on their desired set of capabilities. Scope Industry: life sciences Geography: global Contents In this report, we evaluate clinical D&A platform providers on their: Market adoption and capabilities Case studies and recent developments Strengths and limitations Sourcing considerations Membership(s) Clinical Development Technology Sourcing and Vendor Management

The pandemic accelerated the need to extract value from data as it led to a substantial increase in data generation from various clinical sources, characterized by high veracity, variety, and volume. As a result, there has been a notable surge in the adoption of clinical data and analytics platforms in clinical development. This has sparked considerable interest in assessing their impact on clinical trials, patient care, treatment outcomes, and health system efficiency. Currently, the industry faces a significant challenge in integrating complex clinical data sources, including Electronic Health Records (EHR), Electronic Medical Records (EMR), laboratory data, Clinical Trial Management Systems (CTMS), connected devices, and Real-world Data (RWD). Clinical data and analytics platforms offer significant benefits in the realm of clinical development. These platforms enhance data management by facilitating centralized and standardized data collection from various sources, resulting in improved data quality and integrity. Real-time monitoring capabilities enable stakeholders to track trial progress, identify potential issues, and make informed decisions promptly. Advanced analytics tools help uncover patterns, trends, and correlations within the data, providing valuable insights for optimizing trial protocols and treatment strategies. In this report, we assess 14 clinical Data and Analytics (D&A) platform providers. The providers are positioned on Everest Group’s PEAK Matrix®, a composite index of a range of distinct metrics related to the providers’ capabilities and market impact. The study will enable buyers to choose the best-fit provider based on their sourcing considerations, while providers will be able to benchmark their performance against each other. Scope: Industry: life sciences Geography: global Contents: In this report, we: Examine the provider landscape for clinical D&A platforms Assess clinical D&A platform providers on several capabilities and market success-related dimensions Membership(s) Clinical Development Technology Sourcing and Vendor Management

Clinical trials necessitate extensive planning and involve managing multiple sites, stakeholders, a complicated technology ecosystem, and compliance in a highly regulated environment. Introducing a new drug to the market is a lengthy and laborious procedure that is often accompanied with a significant price tag, averaging around US$2.4 billion. The recent pandemic has significantly influenced clinical trial design and conduct, resulting in a rapid uptake of digital technologies, data science, analytics, and automation tools that improve the efficiency of trial management and workflows. However, the clinical development landscape still has a long way to go, as it remains overly complicated with numerous disconnected systems. This leads to challenges such as data silos, concerns regarding data security and privacy, and the persistence of conventional approaches to data analysis. The unified end-to-end clinical development approach offers a comprehensive solution for efficient trial management that integrates all the necessary solutions for clinical, safety, and regulatory activities with a unified data layer. This approach provides several benefits such as reduced data silos, lower total cost of ownership, and a streamlined product landscape, thereby minimizing the need for integration and custom development activities. This report examines the concept of an end-to-end approach in clinical development, provides insights into current technology implementations, and offers a roadmap for successfully implementing these platforms. Scope Industry: life sciences Geography: global Contents In this report, we: Examine the concept of an end-to-end approach in clinical development Provide insights into the current state of the unification journey Present enterprise expectations from end-to-end clinical development platforms Offer a roadmap for successfully implementing these platforms Membership(s) Life Sciences Information Technology Clinical Development Technology Sourcing and Vendor Management

Decentralized Clinical Trials (DCTs) provide pharmaceutical companies with various benefits, including cost savings, improved patient recruitment and retention, flexible operations, and better data quality. While the technology and data to support DCTs existed before the pandemic, only a few pilots were conducted. Today, the need for remote patient- and site-centric trials has led to increased investments in DCTs by pharma enterprises, and the momentum is expected to accelerate, indicating that DCTs are a lasting trend. Additionally, advances in technology, innovative business models, increased wearables support, regulatory bodies’ push to adopt DCTs, and a holistic approach to clinical trials have strengthened the DCT landscape. In this report, we analyze the current state of the DCT market and deep dive into its adoption, market trends, DCT platform providers’ landscape, enterprise view of DCT platform providers, Environment, Social, and Governance (ESG) initiatives, and emerging technology opportunities in the industry. Scope Industry: life sciences Geography: global Contents In this report, we: Study DCT adoption trends and market dynamics Examine the DCT platform provider landscape Provide an enterprise view of DCT providers Analyze ESG initiatives and emerging technology opportunities in the industry Membership(s) Life Sciences Information Technology Sourcing and Vendor Management

Decentralized Clinical Trials (DCTs), in which clinical trial data is collected through sensors or remote monitoring devices, can deliver many benefits to pharmaceutical companies, including cost savings, better patient recruitment and retention, flexibility in operations, and improved data quality. Before the pandemic, although the technology and data to support DCTs existed, only a few pilots were conducted. Today, the pressing need for remote patient- and site-centric trials has increased investments in DCTs, and the momentum is expected to accelerate going forward, indicating that DCTs are here to stay. Additionally, technology advances, innovative business models, increased wearables support, US FDA’s push to adopt DCTs, and a holistic approach to clinical trials have strengthened the DCT landscape. In this compendium, we provide comprehensive and fact-based snapshots of 24 DCT platform providers. In addition, each provider is positioned on Everest Group’s PEAK Matrix®; for comparison. The compendium will enable providers to benchmark their capabilities against their competitors, while buyers of DCT platforms will be able to assess the providers based on their desired set of capabilities. Scope: Industry: life sciences Geography: global Contents: In this report, we evaluate DCT platform providers on their: Market adoption and capabilities Case studies and recent developments Strengths and limitations Sourcing considerations Membership(s) Life Sciences Information Technology Sourcing and Vendor Management

Decentralized Clinical Trials (DCTs), in which clinical trial data is collected through sensors or remote monitoring devices, can deliver many benefits to pharmaceutical companies, including cost savings, better patient recruitment and retention, flexibility in operations, and improved data quality. Before the pandemic, although the technology and data to support DCTs existed, only a few pilots were conducted. Today, the pressing need for remote patient- and site-centric trials has increased investments in DCTs by pharma enterprises, and the momentum is expected to accelerate going forward, indicating that DCTs are here to stay. Additionally, technology advances, innovative business models, increased wearables support, US FDA’s push to adopt DCTs, and a holistic approach to clinical trials have strengthened the DCT landscape. In this report, we assess the capabilities of 24 DCT platform providers. The providers are positioned on Everest Group’s PEAK Matrix®, a composite index of a range of distinct metrics related to the providers’ capabilities and market impact. The study will enable buyers to choose the best-fit provider based on their sourcing considerations, while providers will be able to benchmark their performance against each other. Scope: Industry: life sciences Geography: global Contents: In this report, we: Examine the provider landscape for DCTs Assess DCT platform providers on several capabilities and market success-related dimensions Membership(s) Life Sciences Information Technology Sourcing and Vendor Management

Remote Patient Monitoring (RPM) is an integrated approach that employs technology-backed medical devices to gather physiological and biometric data from patients that is electronically transmitted for remote analysis, review, and, when necessary, interventions and preventive care. Advances in network technologies, connected devices, medical wearables, sensors, data analytics algorithms, and software are paving the way for efficient data collection in remote clinical trials and the delivery of advanced healthcare. Traditionally, patients had to physically arrive at hospitals or research centers to participate in clinical trials. However, the pandemic and the lockdowns that followed compelled the industry to come up with innovative ways to collect patient data. Decentralized Clinical Trials (DCTs), based on remote data collection and timely data analysis, proved to be indispensable to the clinical research industry over the last two years. As the industry emerges from the pandemic, organizations will continue to accelerate DCT adoption and convert piecemeal deployments into a comprehensive strategy. This report examines the present state of RPM in decentralized trials, the drivers and challenges facing RPM, and the future state of RPM, as well as shares an approach to successfully implement an RPM solution. Scope Industry: life sciences Geography: global Contents In this viewpoint, we: Examine the present state of RPM Evaluate the drivers and challenges for RPM Share the future outlook for RPM Provide a roadmap for the successful implementation of an RPM solution Membership(s) Life Sciences Information Technology Sourcing and Vendor Management